Chikungunya-Pipeline Review, H2 2015

Chikungunya-Pipeline Review, H2 2015

  • Products Id :- GMDHC7238IDB
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chikungunya-Pipeline Review, H2 2015


Global Markets Direct's, 'Chikungunya-Pipeline Review, H2 2015', provides an overview of the Chikungunya's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Chikungunya

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chikungunya

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chikungunya Overview 9

Therapeutics Development 10

Pipeline Products for Chikungunya-Overview 10

Pipeline Products for Chikungunya-Comparative Analysis 11

Chikungunya-Therapeutics under Development by Companies 12

Chikungunya-Therapeutics under Investigation by Universities/Institutes 15

Chikungunya-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Chikungunya-Products under Development by Companies 19

Chikungunya-Products under Investigation by Universities/Institutes 21

Chikungunya-Companies Involved in Therapeutics Development 22

Abivax S.A. 22

Arbovax, Inc. 23

Arno Therapeutics, Inc. 24

Bharat Biotech International Limited 25

Etubics Corporation 26

Indian Immunologicals Limited 27

Inovio Pharmaceuticals, Inc. 28

Integral Molecular, Inc. 29

Merck & Co., Inc. 30

Nanotherapeutics, Inc. 31

PaxVax 32

Profectus BioSciences, Inc. 33

Takeda Pharmaceutical Company Limited 34

Themis Bioscience GmbH 35

Chikungunya-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

ABX-309-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Antibody for Chikungunya-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

AR-12-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

chikungunya vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

chikungunya vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

chikungunya vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

chikungunya vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

chikungunya vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

chikungunya vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

chikungunya vaccine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

chikungunya vaccine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

chikungunya vaccine-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

chikungunya vaccine-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

chikungunya vaccine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

chikungunya vaccine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

chikungunya vaccine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

chikungunya vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

chikungunya vaccine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

chikungunya vaccine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

DEF-201-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

IMCKV-063-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Monoclonal Antibodies for Chikungunya-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

MV-CHIK-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecule to Inhibit NS2 and NS3 for Chikungunya-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Chikungunya-Recent Pipeline Updates 75

Chikungunya-Dormant Projects 78

Chikungunya-Product Development Milestones 79

Featured News & Press Releases 79

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 79

Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 80

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 81

Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 82

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 83

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 83

Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 84

Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 84

Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

Number of Products under Development for Chikungunya, H2 2015 10

Number of Products under Development for Chikungunya-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Comparative Analysis by Unknown Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd...1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Chikungunya-Pipeline by Abivax S.A., H2 2015 22

Chikungunya-Pipeline by Arbovax, Inc., H2 2015 23

Chikungunya-Pipeline by Arno Therapeutics, Inc., H2 2015 24

Chikungunya-Pipeline by Bharat Biotech International Limited, H2 2015 25

Chikungunya-Pipeline by Etubics Corporation, H2 2015 26

Chikungunya-Pipeline by Indian Immunologicals Limited, H2 2015 27

Chikungunya-Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 28

Chikungunya-Pipeline by Integral Molecular, Inc., H2 2015 29

Chikungunya-Pipeline by Merck & Co., Inc., H2 2015 30

Chikungunya-Pipeline by Nanotherapeutics, Inc., H2 2015 31

Chikungunya-Pipeline by PaxVax, H2 2015 32

Chikungunya-Pipeline by Profectus BioSciences, Inc., H2 2015 33

Chikungunya-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 34

Chikungunya-Pipeline by Themis Bioscience GmbH, H2 2015 35

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Stage and Target, H2 2015 38

Number of Products by Stage and Mechanism of Action, H2 2015 40

Number of Products by Stage and Route of Administration, H2 2015 42

Number of Products by Stage and Molecule Type, H2 2015 44

Chikungunya Therapeutics-Recent Pipeline Updates, H2 2015 75

Chikungunya-Dormant Projects, H2 2015 78

List of Figures

Number of Products under Development for Chikungunya, H2 2015 10

Number of Products under Development for Chikungunya-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Top 10 Targets, H2 2015 37

Number of Products by Stage and Top 10 Targets, H2 2015 37

Number of Products by Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Routes of Administration, H2 2015 41

Number of Products by Stage and Routes of Administration, H2 2015 41

Number of Products by Top 10 Molecule Types, H2 2015 43

Number of Products by Stage and Top 10 Molecule Types, H2 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Abivax S.A.

Arbovax, Inc.

Arno Therapeutics, Inc.

Bharat Biotech International Limited

Etubics Corporation

Indian Immunologicals Limited

Inovio Pharmaceuticals, Inc.

Integral Molecular, Inc.

Merck & Co., Inc.

Nanotherapeutics, Inc.


Profectus BioSciences, Inc.

Takeda Pharmaceutical Company Limited

Themis Bioscience GmbH

Chikungunya Therapeutic Products under Development, Key Players in Chikungunya Therapeutics, Chikungunya Pipeline Overview, Chikungunya Pipeline, Chikungunya Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]